Feb 12 (Reuters) - Takeda Pharmaceutical's (4502.T), opens new tab therapy for an allergic inflammation of the esophagus has received approval from the U.S. FDA, the Japanese drugmaker said on Monday, ...
Takeda (TAK) is rated 'HOLD' with a $12/share price target, reflecting limited upside and persistent execution risks. TAK's fundamentals are solid, but volatile earnings, poor forecast accuracy, and ...
Most disputes between pharmaceutical companies and generic drugmakers end in settlements. Five years of class-action litigation over a Takeda Pharmaceutical gastrointestinal drug culminated this week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results